Review papers with raw data transparency

Quick visual summary (scores from paper metadata)

What Gomazkov claims (short bullets, each supported below)

• Immune dysregulation (discordant innate/adaptive responses) is central to PCS.
• Persistence of viral antigen (S1, N) in tissues or cells helps sustain inflammation and symptoms.
• Endothelial dysfunction, microcirculatory disturbance and coagulopathy amplify multi‑organ damage.
• Autoantibodies and autoreactive B/T responses contribute to heterogeneous phenotypes.
• Biomarker panels and immune phenotyping should guide personalized therapy.

Representative primary/secondary evidence Gomazkov cites (selected, with concise extracts)

1. Gomazkov 2024 (review)
2. Phetsouphanh et al. 2022
3. Swank et al. 2023
4. Espín et al. 2023 (biomarkers review)
5. Cevik et al. 2021

Critical appraisal — strengths and limitations (evidence‑first)

How Gomazkov's synthesis matches high‑quality recent findings

High‑quality cohort and mechanistic papers converge on a multi‑pathway model: (A) in a subset of patients, persistent antigen or viral fragments (anti‑N/anti‑S kinetics differ between PCC and recovered cohorts) are measurable and associate with PCS; (B) immune signatures (persistent innate activation, altered T/B subsets, cytokine triads IL‑1β/IL‑6/TNF) are reproducible across cohorts; (C) endothelial/complement/coagulation activation shows repeated signal in proteomics cohorts. Gomazkov correctly centers the immune system but overstates generality without subgroup stratification (Virus Watch antibody trajectories 2025Schultheiß et al. 2022 (cytokine triad)).

Practical implications and where evidence is strong vs weak

• Strong evidence (moderate–strong): immune alterations persist in a subset of patients and correlate with symptoms; antigen persistence measurable in subgroups; complement/endothelial signals repeatedly appear in proteomics/cohort studies (Phetsouphanh et al. 2022Espín et al. 2023).
• Weaker / contested areas: universal antigen persistence as the single cause of PCS (many patients lack detectable spike/N despite symptoms), direction of causality (immune dysregulation could be both cause and effect), and which interventions reliably alter long‑term outcomes (Cevik et al. 2021).

Visual: frequency of key mechanistic themes in Gomazkov's narrative (derived from paper text & reference topics)

Note: the pie encodes narrative emphasis in the review (how often themes and supporting citations appear), not quantitative patient data; used only to visualise the review's focus and to show how the author prioritises mechanisms.

Falsifiability: what would refute Gomazkov's central claim?

1. Large, prospective cohorts showing that PCS incidence and severity are unrelated to persistent antigen detection or persistent immune signatures after adjusting for confounders would contradict antigen/immune‑centric causality (Virus Watch 2025).
2. Randomized immunomodulatory interventions that suppress the reported immune signatures but do not change PCS clinical outcomes would challenge immune‑driven causation.

Concrete recommendations for improved science & for clinicians reading Gomazkov

• Use prospective, pre‑specified cohort designs with standardized specimen types (EDTA plasma vs serum) and harmonized assays to reduce interstudy heterogeneity (JCI Insight complement review 2025).
• Attempt stratification early: identify antigen‑positive vs antigen‑negative PCS subgroups and report results separately — this will clarify which mechanisms apply to which patients.
• Avoid overgeneralization: label conclusions per subgroup and state explicitly where evidence is weak or correlative.

Bottom line (short)

Gomazkov provides a concise, up‑to‑date narrative arguing that immune dysregulation and antigen persistence are central to PCS. This is consistent with multiple cohort and mechanistic studies, but the review's narrative (non‑systematic) design, interstudy heterogeneity, and incomplete attention to null/contradictory data lower its evidentiary weight. The review is useful as a synthesis and hypothesis generator but should not be taken as definitive proof of a single, universal PCS mechanism (Gomazkov 2024 conclusion).